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Abstract
Purpose—To provide a review of the status of biomarkers in cystic fibrosis drug development, 
including regulatory definitions and considerations, a summary of biomarkers in current use with 
supportive data, current gaps, and future needs.
Methods—Biomarkers are considered across several areas of CF drug development, including 
cystic fibrosis transmembrane conductance regulator modulation, infection, and inflammation.
Results—Sweat chloride, nasal potential difference, and intestinal current measurements have 
been standardized and examined in the context of multicenter trials to quantify CFTR function. 
Detection and quantification of pathogenic bacteria in CF respiratory cultures (e.g.: Pseudomonas 
aeruginosa) is commonly used in early phase antimicrobial clinical trials, and to monitor safety of 
therapeutic interventions. Sputum (e.g.: neutrophil elastase, myeloperoxidase, calprotectin) and 
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blood biomarkers (e.g.: C reactive protein, calprotectin, serum amyloid A) have had variable 
success in detecting response to inflammatory treatments.
Conclusions—Biomarkers are used throughout the drug development process in CF, and many 
have been used in early phase clinical trials to provide proof of concept, detect drug bioactivity, 
and inform dosing for later-phase studies. Advances in the precision of current biomarkers, and the 
identification of new biomarkers with ‘omics-based technologies, are needed to accelerate CF drug 
development.
Introduction
Cystic fibrosis (CF) is caused by mutations in a gene coding the cystic fibrosis 
transmembrane conductance regulator (CFTR) protein, an ion channel regulating chloride, 
bicarbonate, sodium and fluid fluxes at epithelial surfaces (1). While there have been steady 
improvements in outcome, median predicted survival for a newborn with CF in the United 
States in 2014 was 41 years, and median age of death in 2014 was 28 years (Cystic Fibrosis 
Foundation 2014 Patient Registry Report) underscoring the need for better treatments. CF 
lung disease is characterized by defects in ion transport, mucociliary clearance, 
inflammation, bacterial infection, and airway remodeling that culminates in bronchiectasis 
and respiratory failure. CFTR may also cause intrinsic abnormalities in host defense cells 
including epithelia, neutrophils and macrophages.
Given its complex pathophysiology, the U.S. CF Foundation (CFF), academic investigators, 
industry partners and other sponsoring agencies have taken a multipronged approach 
targeting the different elements of CF pathophysiology. In particular, efforts aimed at 
treating Pseudomonas aeruginosa infection, thinning CF mucus and restoring airway surface 
liquid have shown clinical benefit but have not halted decline in lung function. Recently, a 
new class of agents termed CFTR modulators has had clinical impact (dramatic lung 
function improvement with ivacaftor for patients with CFTR gating mutations; modest with 
lumacaftor-ivacaftor for F508del homozygous patients) (2-5). However, other measures 
more sensitive than lung function may accelerate drug testing and biomarkers are becoming 
recognized as a critical tool for CF drug development.
A biomarker, by US Food and Drug Administration (FDA) definition, is “a characteristic 
that is objectively measured and evaluated as an indicator of normal biological processes, 
pathogenic processes, or biological responses to a therapeutic intervention” and offers great 
promise to speed drug development (6). The potential uses of biomarkers in drug 
development include enabling assessment of safety, efficacy, and patient selection for the 
purpose of enrichment. The FDA recognizes the importance of biomarkers and drafted a 
qualification process that addresses aspects of biomarker development and clinical utility 
(7); here are great challenges to meeting this rigorous qualification process for a rare disease 
such as CF (8).
To advance biomarkers in CF drug development, the CFF has convened a CF Biomarker 
Consortium consisting of investigators with particular expertise in biomarker research. This 
document focuses on biomarker validation and qualification for assessing CFTR function 
and detection, infection, and inflammation, examines relationships of existing biomarkers to 
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established clinical outcomes in CF, highlights new technologies for biomarker 
development, and summarizes areas requiring further development.
Biomarker Validation and Qualification Within The Context of Utilization
As biomarkers for CF drug development are advanced, their application or utilization will 
dictate the necessary validation and qualification process. All biomarkers to be used in the 
context of drug development should reliably and sensitively capture the biologic activity of a 
therapy. Hence, any novel assay, procedure, or test must be validated for its ability to 
accurately and reproducibly measure a biologic process. Beyond biomarker validation, 
additional qualification of a biomarker would establish a linkage with clinical outcomes 
(clinical validity); validation of such a linkage strengthens the utilization of the biomarker 
throughout later phases of clinical development and in rare cases can promote a biomarker to 
the level of a surrogate endpoint that substitutes for a clinical endpoint in pivotal registration 
trials (8, 9).
It is important to recall that the role of biomarkers throughout drug development, and 
particularly in early phase studies, is to demonstrate biological efficacy of new therapies, 
confirm mechanism of action, and inform dose selection. Biomarkers used in early phases of 
drug development do not require qualification, or even evidence of strong correlation with 
measurable clinical outcomes. In early phases they can be used to explore and inform go/no 
go decisions regarding later-phases, but notably the level of risk to the overall development 
program is ultimately dependent on confidence that promising biomarker results will predict 
clinical efficacy.
Biomarkers typically play a supportive role to confirm mechanism of action in later-phase 
studies, however in some settings it may be desirable for them to replace traditional clinical 
efficacy measures in order to streamline drug development by enabling more rapid 
assessment of efficacy with potentially fewer numbers of patients. In most cases this would 
require that the biomarker meets qualification standards as a surrogate endpoint for clinical 
efficacy (7). Surrogate endpoints serve as substitutes for accepted measures of clinical 
efficacy and can accelerate drug approval by responding over a shorter duration (e.g. 
compared to survival), or by requiring fewer study participants because of increased 
measurement precision. The process of qualifying a biomarker as a validated surrogate 
endpoint for phase 3 trials requires that the marker correlate with a meaningful clinical 
endpoint and capture the net effect of the intervention or drug on the efficacy endpoint (10). 
The latter is more difficult to achieve because it demands that late-phase studies 
simultaneously capture the biomarker and the clinical endpoint to evaluate predictive net 
effect (11). To date, no biomarker has formally gone through the qualification standards of a 
surrogate endpoint for clinical efficacy in CF. Importantly, however, there are instances in 
other rare diseases, such as Fabry's disease, for which a non-validated surrogate endpoint of 
a physiologic biomarker of disease has been used as a pivotal endpoint in a registration trial 
(12).
While more traditional drug development focuses on prognostic biomarkers that are 
correlates of disease outcome and are intervention-independent, there is also a role for 
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predictive biomarkers in drug development which offer information that is more specific to a 
particular intervention. Predictive biomarkers have been an area of focus for many years in 
oncology research (13). In a drug development program, a predictive biomarker may be an 
analyte, gene, or protein that identifies candidate study participants who are more likely to 
benefit from treatment and enable enrichment trials that are meant to optimize trial 
outcomes. As with the more general classification of biomarkers, development and 
validation of predictive biomarkers generally demands rigorous, multi-staged assessment of 
their clinical utility through retrospective and prospective controlled trials (14).
As in any rare disease setting, opportunities for flexibility in this rigorous process balanced 
against level of risk will be necessary given the limited patient population. Strategic 
utilization of biospecimens and well characterized phenotypic data in conjunction with 
rigorous study design and close collaboration with regulatory agencies are essential for 
advancing biomarkers in CF.
Cf Relevant Pulmonary Biomarkers: Current Status and Opportunities
Progressive lung disease is the primary cause of CF morbidity and mortality, and a critical 
target for therapeutic development. Several therapies have been developed to address CF 
lung pathologies, and their clinical use has been associated with improved outcomes. The 
most common primary outcome measures supporting regulatory approval of CF pulmonary 
therapies are discussed below. Physiologic outcome measures have recently been published 
(15).
Accepted Clinical Efficacy Measures in CF
Change in FEV1 has become one of the most established endpoints to demonstrate clinical 
efficacy in CF clinical trials (2, 4, 16-18). Pulmonary exacerbations (risk, frequency, time to) 
have also served as primary clinical efficacy endpoints, but typically require larger and 
longer studies to demonstrate treatment impact. Important secondary measures that have 
supported approval and clinical use of pulmonary therapies include patient reported 
outcomes (e.g.CF Quality of Life – Revised instrument), weight gain and bacterial density 
(4, 18-22). To date, no CF-specific anti-inflammatory drug has gone through regulatory 
approval and thus there has been little guidance as to what the accepted clinical efficacy 
measures will be for these agents, which have not produced the type of immediate and 
sustained FEV1 improvement observed with mucolytics, antibiotics, or CFTR modulators 
(23, 24).
Need for More Sensitive Clinical Efficacy Endpoints
Important gaps that have emerged include relevant outcome measures for patients with either 
mild or advanced lung disease, and young CF patients who typically have both mild disease 
and poorly standardized outcome measures. Multiple breath washout testing and the Lung 
Clearance Index as recently published (15) has advanced as a putative endpoint with greater 
sensitivity than FEV1 to detect biologic effect in younger patients with mild lung disease, 
and are currently included in several CF clinical trials. Imaging may serve as a correlate of 
structural lung injury (e.g. bronchiectasis). The remainder of this review will examine the 
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existing data supporting the validity and qualifications of several biomarkers of CFTR 
activity, infection and inflammation, and the investigations needed to optimize these 
biomarkers for use in CF drug development.
Cftr Activity and Ion Transport in Vivo
There are three in vivo biomarkers of ion transport which have primarily been used to 
monitor restoration of CFTR function. These include sweat-chloride concentration, nasal 
potential difference (NPD) measurement, and intestinal current measurement (ICM). Sweat-
chloride is a simple, portable, and reliable test of CFTR function that clearly discriminates 
between patients with minimal, partial and full CFTR activity (25, 26). It has been carefully 
standardized for both clinical use and for incorporation into clinical trials, and remains the 
mainstay of CF diagnosis. Different levels of CFTR function quantified by the sweat-
chloride test also correlate with important markers of disease severity, including age of 
diagnosis (pre-newborn screening), pancreatic sufficiency, isolated male infertility, 
microbiology, and lung disease severity (25-30). Profound reductions in sweat-chloride have 
been observed in all studies of ivacaftor monotherapy in CF patients with gating mutations 
(3, 5, 31-34). Intermediate effects were observed with ivacaftor in CF patients with the 
R117H mutation, and smaller effects in CF patients with two copies of the F508del CFTR 
mutation treated with ivacaftor or ivacaftor/lumicaftor (35-37). The effects of CFTR 
modulators on sweat chloride generally parallel the clinical benefits observed for these three 
populations (FEV1, risk of pulmonary exacerbations – see Table 1). While individual 
changes in sweat-chloride have not correlated directly with FEV1 improvements (38, 39), 
aggregate data have demonstrated excellent assay performance and detection of biologic 
activity. Future studies utilizing sweat-chloride will need to monitor long term relationships 
between sweat-chloride and key clinical outcomes in CF to support this biomarker as a key 
measure to accelerate drug development.
NPD is a direct measure of CFTR function in respiratory epithelium, and isolates CFTR 
activity across the nasal mucosa independent of sodium transport and the activity of other 
chloride transporters (40, 41). It is more difficult to perform than sweat- chloride, and 
requires specialized equipment and extensive training. Recent efforts have standardized NPD 
performance and analysis across the US and Europe, including SOPs and centralized 
coordination and interpretation of trial data (42-46). It has been incorporated into small 
investigator-initiated trials of CFTR and other ion transport modulators (47-50) and also into 
early phase trials of CFTR modulators that proceeded to seek regulatory approval (3, 46). In 
multi-center trials, NPD measurements had sufficient sensitivity to detect dose-dependent 
bioactivity of ivacaftor in patients with the G551D CFTR mutation, but failed to detect 
bioactivity of systemic ataluren or lower-dose lumacaftor monotherapy in phase 2 and 3 
studies performed in patients with PTC and F508del mutations, respectively (3, 44). Neither 
of these interventions had measurable clinical benefits, suggesting that the NPD assay may 
be specific for clinically relevant modulator bioactivity. Studies focused on improving NPD 
reliability and examining relationships between CFTR (or other ion transporter) restoration 
and clinical response are gaps in CFTR biomarker development and would clarify the future 
role of this assay in CF drug development.
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ICM is another assay that can isolate CFTR function, and has the advantage of a large 
dynamic range between CF and non-CF (28, 51-54). Rectal biopsies are dissected and then 
studied in Ussing chambers to monitor CFTR-dependent ion transport ex vivo. Like NPD, 
efforts have standardized ICM performance, and a universal SOP has been adopted by both 
US and European centers with centralized data interpretation for use in multicenter clinical 
trials (53, 55). Like sweat- chloride and NPD testing, ICM can clearly discriminate different 
levels of CFTR function based on CFTR genotype (nonfunctional, partial and full function) 
with clinical correlates dependent on level of CFTR activity (28, 51). Demonstrating 
reliability of ICM is difficult due to the need for repeated biopsies, and performance of the 
assay is limited to centers with expertise in specialized electrophysiologic measurements. 
For these reasons, ICM will likely remain an early phase CFTR biomarker performed in a 
limited number of standardized centers.
Biomarkers of Infection
Viral and fungal infections are critical aspects of CF lung disease, but infection with defined 
pathogenic bacteria such as Pseudomonas aeruginosa, Burkholderia cepacia complex and 
methicillin resistant Staphylococcus aureus are linked to CF morbidity and mortality 
(56-60). Thus, developing anti-microbial interventions is a key goal of CF therapeutics. 
Infection can be considered as a progression from early transient infections to chronic, often 
biofilm-dominated conditions that are poorly reflected in vitro (61, 62).
The most direct biomarkers of infection are from the lower respiratory tract 
(bronchoalveolar lavage (BAL) fluid, sputum) but other sources such as cough swabs, 
oropharyngeal swabs and nasopharyngeal (NP) samples are used in non-expectorating 
patients, albeit with unclear sensitivity and specificity for lower airway tract infection that 
limits their applicability to drug development.
Commonly used biomarkers for antimicrobial studies include bacterial density (CFU/g for 
sputum or CFU/mL for BAL fluid) and/or detection of CF pathogens as primary or 
secondary endpoints. Only drugs treating chronic Pseudomonas infection have sought 
regulatory approval, and relied on reduction in microbial density as a key supportive 
endpoint (17, 63-65). However in many trials change in FEV1 is the primary endpoint and 
this may not always overlap with reductions in Pseudomonas density (66).
Targeted PCR-based detection, which is routine for viruses, is being introduced to detect CF 
bacteria, yet these methods have not been used extensively (67, 68). Panels to detect 
frequently encountered bacteria are in development, and are often based on detection of 
bacterial enzymes or virulence factors that may enable early detection of resistance.
The CF Lung Microbiome
Evaluation of the CF lung microbiome (through unselected detection of 16S ribosomal 
bacterial RNA using deep sequencing methods) is an emerging technology. Microbiome 
studies to date have generally shown that decreased measures of microbial diversity are 
associated with more advanced disease and may change prior to exacerbations (69-71). 
Methodological differences in extraction and sequencing, poor distinction of live vs. non-
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viable bacterial DNA, and the lack of quantitation are current limitations to their clinical and 
biomarker use. Detection of bacteria using molecular methods has enhanced sensitivity and 
potentially may reduce processing times, but monitoring of disease status and drug effect via 
molecular detection and microbiome analysis remains exploratory.
Future directions include functional evaluation of the microbiome either through interactions 
between taxa and/or changes in metabolic activity correlating to clinical outcomes. To 
examine metabolic activity, DNA and RNA based metagenomics or metatranscriptomics (i.e. 
the study of the function/activity of the transcriptome -RNA-seq) have been used. Technical 
challenges include contamination with human genetic material and mapping of sequence 
data (72). Early reports indicate that DNA based (total) and RNA based (metabolically 
active) community structure show overlap for the predominant taxa, but less prevalent 
organisms may be metabolically very active (73). Further, metabolic activities in CF samples 
show less patient-to-patient variation than the total microbiome and differ from results in 
other pulmonary conditions (74), and metabolic profiles of bacteria are dynamic with 
adaptation to the lung disease (75). Although limited to small study numbers, early findings 
suggest changes in disease status based on exhaled volatile bacterial metabolites (76). 
Measuring bacterial volatile organic compounds and inflammation may allow rapid 
monitoring of lung disease progression. Methods may include ‘electronic noses’ that 
distinguish patterns of volatile organic compounds rather than specific compounds, and have 
the benefit of portability. Technical challenges, standardization, contribution of non-
respiratory vs. respiratory factors, and defining CF vs. non-CF patterns remain barriers to 
overcome prior to their use as biomarkers for antimicrobial therapies (77).
Biomarkers of Inflammation
Inflammatory biomarkers could play a critical role in the development of anti-inflammatory 
drugs, and reflect downstream improvements in CF lung disease for disease-modifying 
treatments. They could be used in early phase studies to confirm the proposed mechanism of 
action of drug candidates. Alternatively, as correlates of clinical endpoints, they could help 
select agents for further Phase 3 investigations. Results from previous CF clinical trials 
indicate that anti-inflammatory therapies may not result in immediate improvements in 
pulmonary function, but could slow the rate of lung function decline (23, 24). This requires 
many patients being studied over a prolonged period to demonstrate efficacy, highlighting 
the urgency of identifying biomarkers that can more rapidly screen candidate drugs.
Lung-derived Biomarkers of Inflammation
The most direct method to assess CF lung inflammation is via bronchoscopy with BAL. 
BAL inflammatory markers have been used as clinical endpoints in pathophysiological 
studies (e.g. Australian Respiratory Early Surveillance Team for CF) (78, 79), and in clinical 
trials of inhaled tobramycin (80) and recombinant human DNase (81). A recently published 
document from the European CF Society Clinical Trial Network concluded that the use of 
BAL in clinical research should be limited due to its invasive nature, but that it may be 
applicable to early-phase clinical trials conducted in specialized centers and in trials 
involving young children with early/mild lung disease (82).
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Due to drawbacks of bronchoscopy, the two most commonly collected biospecimens to 
measure inflammation are sputum and blood. Spontaneous sputum expectoration is 
generally limited to those with more advanced lung disease (adolescents and adults). Sputum 
induction (inhalation of hypertonic saline) improves sample acquisition in individuals who 
do not routinely expectorate sputum, and biomarker measurements are reasonably 
comparable between induced and spontaneously expectorated sputum (83-85). For studies in 
which the primary outcome is a sputum biomarker in children and/or those with preserved 
lung function, sputum induction likely should be performed throughout the trial. When 
sputum biomarkers are secondary outcomes, collecting spontaneously expectorated sputum 
(with induction as a back-up) is a reasonable approach.
The validity of sputum biomarkers as endpoints in CF clinical trials has been extensively 
reviewed (85). Neutrophil elastase (NE) is currently the most informative sputum biomarker 
to monitor CF lung disease. Sputum NE activity correlates with bronchiectasis in CF (86), 
tracks with and is predictive of future lung function decline (87, 88), relates to treatment 
response in pulmonary exacerbations, and predicts time to next exacerbation (89, 90). 
Increased BAL NE is also a predictive biomarker of impaired lung function and 
bronchiectasis in young children with CF (79). Other sputum biomarkers that are associated 
with and predictive of key clinical events in CF include calprotectin (91), myeloperoxidase 
(92), high-mobility group box 1 (HMGB-1) (93, 94), and YKL-40 (95).
A proof of concept study assessing the responsiveness of sputum biomarkers to intravenous 
antibiotic treatment during pulmonary exacerbations demonstrated that decreases in sputum 
inflammatory markers, correlated with pulmonary treatment response (89). These findings 
though were not replicated in a more recent study of exacerbation treatment (96). 
Differences in sputum NE were observed over a six month study of azithromycin compared 
with placebo (19), but more recent interventional trials using sputum inflammatory 
biomarkers have generally failed to show significant changes in NE activity and other 
sputum biomarkers (except for modest reductions in sputum IL-6 (97-99)). Also, ivacaftor, 
which has been shown to improve many clinical outcomes, did not change sputum 
inflammatory biomarkers in a G551D CF cohort (33). The lack of treatment effect in these 
studies may be due in part to the intrinsic variability, particularly between-subject variance, 
of sputum biomarkers (99). This variance makes it challenging to rely upon sputum 
biomarkers during drug evaluation over short treatment periods, and sputum biomarkers may 
only be sufficiently sensitive to demonstrate anti-inflammatory effects in longer trials (≥ six 
months). To minimize the potential effects of sputum collection and processing on 
biomarker variability, recommendations include using SOPs (sputum induction, processing), 
centralized laboratories for sputum processing and analysis (CFF National Resource 
Centers: https://www.cff.org/Our-Research/Therapeutics-Development-Network/Working-
with-the-TDN/National-Resource-Centers/), training of research personnel, and ensuring 
quality control (85).
Blood-based Biomarkers of Inflammation
Systemic inflammatory markers would be ideal since blood measurements are easily 
standardized, repeatable, and can be obtained from subjects of any age and disease severity. 
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Systemic inflammation may also link pulmonary and non-pulmonary comorbidities of CF. 
While there are less data correlating systemic inflammation with clinical outcomes in CF, 
systemic inflammatory biomarkers correlate with key clinical events including pulmonary 
exacerbations and lung function decline (100-104). Circulating biomarkers have consistently 
changed more than sputum markers of inflammation with exacerbation treatment (91, 96, 
105), suggesting that systemic inflammatory measures may be more sensitive in short term 
interventional studies focused on mitigating exacerbations. Based on results from a 
multicenter exacerbation study (106), serum C reactive protein (CRP), serum amyloid A 
(SAA) and calprotectin declined during azithromycin treatment in a CF interventional trial 
(107). These reductions correlated with improvements in lung function and weight gain, 
providing indirect evidence that the changes were associated with clinically meaningful 
outcomes. Other candidate systemic biomarkers relating clinical status to CF outcomes 
include neutrophil elastase antiprotease complexes (NEAPC) (101), various cytokines 
including interleukin-6 (many studies), IgG (100), and circulating mononuclear cell RNA 
transcripts (108).
Additional studies are required to develop sputum and systemic inflammatory biomarkers 
for CF drug development. We must determine associations between inflammatory 
biomarkers and key clinical outcomes (FEV1 decline, pulmonary exacerbations) in broader 
CF populations, which will be facilitated through biospecimen collection in longitudinal 
studies. We need to know whether short term changes in inflammatory biomarkers predict 
longer term clinical outcomes, and how airway and systemic inflammation may change with 
CFTR modulators. Additional data examining the effects of freezing and delayed sputum 
processing on analyte measurements are required, and would inform multicenter trials that 
collect sputum samples and perform centralized processing and analysis.
New Technologies and Tools
‘Omics-based Biomarker Development for New CF Therapeutics
The use of ‘omics based tools to identify and validate biomarkers relevant to CF pathologies 
have only recently begun to be applied, and elevation to regular biomarker use is not 
established. These tools allow for an unbiased analysis of complex cellular processes in a 
variety of substrates. Discovery of novel molecular biomarkers in CF has to date been 
limited, and the majority of discovered biomarkers represent acute response markers. 
Furthermore, no molecular biomarkers have been shown to reliably predict acute or chronic 
CFTR restoration. The advent of novel approaches in high throughput technologies coupled 
with advancements in analysis of “big data” may allow investigators to ask important 
questions with high sensitivity and precision.
Gene-array studies have suggested the dysregulation of numerous pathways in CF. In an 
elegant study Wright and colleagues examined gene expression in the nasal epithelia of CF 
patients with either mild or severe lung disease (109) and identified abnormalities in gene 
expression regulating lipid metabolism, ubiquination, and mitochondrial/whole-cell redox 
regulation that segregated cohorts by disease severity. More recently, Nick and colleagues 
identified a panel of RNA transcripts that were predictive of pulmonary exacerbations (108). 
All of these observations require validation prior to clinical extension.
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Mass spectrometry (MS)-based proteomics and/or metabolomics have been used for either 
non-biased or targeted/selected biomarker discovery, with lipidomics gaining much recent 
interest. MS can precisely and rapidly examine markers of disease or response to therapy 
broadly, allowing for global analyses of individual samples in a non-biased, data-driven 
approach. Metabolomic analyses of non-fasted CF patients revealed a decrease in β-
oxidation of fatty acids, which is a marker of mitochondrial dysfunction (110), and CF 
plasma lipidomic studies have detected significant decreases in anti-inflammatory lipids 
(111). In CF sputum, a metabolomic/lipidomic analysis by Yang and colleagues identified a 
number of proinflammatory lipids (oxylipins) previously not identified in the CF lung (112). 
These studies also found a significant decrease in lipoxin A4 in CF lungs, which had 
previously been identified and validated by other approaches (113). The fact that these broad 
analysis studies also accurately detected the known lipoxin A4 deficiency in CF increases 
confidence in the application of MS-based lipidomic analyses in CF.
In the case of proteomics, no broad analysis of markers of CF disease progression in serum 
has been reported. Studies have focused on CF versus non-CF comparisons, which require 
less extensive analyses to identify differences versus studies where all cohorts have CF with 
varying degrees of disease. Proteomic analysis of CF sputum discovered a relationship 
between myeloperoxidase, protein oxidation and pulmonary inflammation (114), which was 
validated in BAL (115). When the proteome of CF-patient nasal epithelia was examined, a 
significant decrease in the expression of a number of anti-inflammatory proteins was 
detected (116). Proteomic screens have discovered a previously unknown mechanism for 
antioxidant downregulation in CF, namely Nrf2 dysfunction (117, 118). Follow-up 
biochemical studies in CF primary tissues linked this dysfunction to increased inflammatory 
signaling, and demonstrated that activation of Nrf2 in CF mice produced anti-inflammatory 
benefits (119). These results highlight the potential of non-biased proteomic analyses in 
discovering novel biomarkers and previously unknown mechanisms of disease.
Although ‘omics approaches hold much promise for biomarker discovery in CF, it is 
important to note that MS-based analyses are semi-quantitative, and therefore it is essential 
that observations made in proteomic, metabolomic, and lipidomic studies are validated by 
other approaches. Furthermore, while instrumentation has improved, the techniques used to 
conduct proteomic analyses also vary and can influence results significantly. Standardization 
of methodology, data analysis and incorporation of these tools into therapeutic clinical trials 
offers the opportunity to fully realize the promise of these technologies to advance CF care 
and drug development.
Summary, Needs and Conclusions
The status of biomarkers to advance CF therapies varies considerably across the different 
pathogenic targets. Many CF biomarkers have demonstrated their ability to inform early 
drug development by assessing drug bioactivity and potentially enabling dose selection for 
trials. Sweat chloride appears to be a biomarker with great potential to guide early phase 
CFTR modulator development and enable regulatory decision making, and further studies 
examining relationships between improvements in sweat- chloride and long term outcomes 
may broaden the utilization of this biomarker. NPD and ICM can also provide supportive 
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data of bioactivity, but technical challenges limit these biomarkers to early phase trials. 
Biomarkers of infection including sputum bacterial density and pathogen detection remain 
valuable tools for early phase trials. Molecular platforms to assess the microbiome (and host 
response) also hold promise to advance biomarkers of airway infection and drug activity, and 
standardization of techniques coupled with their incorporation into studies of new therapies 
are required to understand their role in drug development. Inflammatory biomarkers in 
sputum (NE) and blood (CRP, calprotectin, SAA) correlate with clinical status and 
interventions, but gaps in our understanding of CF inflammation are a limitation to the 
development of novel CF anti-inflammatories. The revolution in ‘omic technologies over the 
past decade is beginning to identify novel biomarkers of various disease manifestations, but 
advances in data analysis and the need for candidate validation are critical before these 
technologies become mainstream players in CF drug development. We hope that this review 
serves as a valuable summary of biomarkers relevant to CF therapeutics, and guides future 
research to advance this field and to accelerate the development of new treatments for CF 
patients.
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Table 1
Impact of CFTR Modulators on Sweat-Chloride in Clinical Trials
*
 Ivacaftor monotherapy
Enrollment (number 
on modulator)
Change in sweat [chloride] 
(treatment effect)
Accurso (4) (G551D, >18 yrs) N = 8 -42.3 mM (p<0.01)
Ramsey (5) (G551D, >12 yrs) N = 83 -48.1 mM (p<0.001)
Davies (34) (G551D, 6-11 yrs) N = 26 -54.3 mM (p<0.001)
Davies (36) (gating, 2-5 yrs) N =19 -46.9 mM (p<0.001)
De Boeck (6) (gating, age >6 yrs) N = 39 -49.2 mM ((p<0.001)
Moss (37) (R117H, >6 yrs) N =34 -21.9 mM ((p<0.001)
Rowe (35) (G551D, >6 yrs) N = 151 -53.8 mM (p<0.001)
Flume (39) (F508del/F508del, >12 yrs) N = 112 -2.9 mM (p=0.04)
Lumacaftor monotherapy Lumacaftor/ivacaftor co-therapy Enrollment (number on 
modulator)
Change in sweat [chloride] 
(treatment effect)
Clancy (45) (lumacaftor, 200 mg every 24 hrs, F508del/F508del, >18 yrs) N = 19 -8.21 mM (p<0.01)
Boyle (38) Lumacaftor 400 mg every 12 hrs and ivacaftor 250 mg every 12 
hrs, F508del/F508del, >18 yrs) N = 11 -10.3 mM (p=0.002)
*Studies listed by lead author, with genotype and age of enrolled subjects as noted. Patients >6 yrs of age were dosed with ivacaftor 150 my every 
12 hrs. Patients age 2-5 years were dosed with ivacaftor based on weight.
†
Dose of lumacaftor and ivacaftor as noted.
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Table 2
Microbial Biomarkers in Acute and Chronic Infection
Infection Biomarker Early infection Chronic infection
Culture: Presence or CFU/mg 
(mL)
Common biomarker for antibiotic development 
May be of interest in CFTR specific therapies
Small changes in density with most therapies. May 
show changes with antimicrobials and CFTR 
modulators.
*Molecular detection and 
diversity measures
No differences prior to onset of a primary 
pathogen, followed by decreasing diversity with 
advance in disease.
Long term decrease with advanced disease. Short term 
changes less pronounced. Internal consistency within 
a given patient.
Bacterial metabolites
Few data available and low bacterial biomass 
compared to host derived signal, thus many 
signals represent host inflammation.
Changes in bacterial phenotypes and metabolites with 
disease progression. Some could serve as markers of 
disease severity.
Measures of bacterial 
cooccurrence
Few data are currently available, but indicate 
competition and communication.
Need to develop network analyses – not yet 
informative for pathogenesis or disease severity.
*
Diversity can be measured using extensive culture conditions, but typically considered a measure in microbiome studies measuring relative 
abundance.
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